Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.
Profitability
This table compares Connect Biopharma and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -182.86% | -127.70% |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
Earnings and Valuation
This table compares Connect Biopharma and Pyxis Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $2.95 million | 13.40 | -$55.48 million | ($1.14) | -0.55 |
| Pyxis Oncology | $11.04 million | 18.20 | -$79.62 million | ($1.30) | -1.29 |
Connect Biopharma has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Connect Biopharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Connect Biopharma and Pyxis Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
Connect Biopharma currently has a consensus price target of $5.88, suggesting a potential upside of 835.21%. Pyxis Oncology has a consensus price target of $8.71, suggesting a potential upside of 418.71%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Connect Biopharma is more favorable than Pyxis Oncology.
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 10.5% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Connect Biopharma beats Pyxis Oncology on 9 of the 13 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
